Kaixinren And Nikko Cordial Securities Sign Agreement
This article was originally published in PharmAsia News
After receiving 100 million yuan in funding from Nikko Antfactory at the beginning of this year, Kaixinren chain drugstore has signed an agreement based on adjustable evaluation with Nikko Cordial Securities, which controls Nikko Antfactory. Nikko Antfactory will continue to pump $30 million yuan to $50 million yuan into Kaixinren within the next two years, with a goal of Kaixinren getting listed by 2010. Kaixinren has set out a 10-year strategy that includes opening 1,000 shops in three years, then gradually building up to 1,800 stores to become a world-class pharmaceutical corporation. It also aims to hit sales of 10 billion yuan within five to ten years. (Click here for more - Chinese Language)
You may also be interested in...
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.